Welcome back! Today we have a very special episode on Alprazolam, brand-name Xanax. This benzodiazepine is one of the most commonly-prescribed and sought out psychotropic medications.

• https://www.ncbi.nlm.nih.gov/books/NBK538165/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC6769182/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC5846112/

• https://pubmed.ncbi.nlm.nih.gov/6141930/

  https://pubmed.ncbi.nlm.nih.gov/17514187/

Join us today for an episode on the impact of climate change on mental health. We'll be exploring concepts like eco-anxiety, advocacy, the impact of nuclear war and practical tips.

We're joined by guest Dr. Ferdnand Osuagwu, who was the former Chair of the Caucus on Climate Change and Mental Health of the American Psychiatric Association (APA) and founder of the Ferdnand Foundation International, an organization dedicated to underserved and marginalized populations and with a particular emphasis on addressing their needs in the areas of health, education, climate change, social justice and resource mobilization. 

Ferdnand Foundation Website: https://ferdnandfoundation.org/

Ferdnand Foundation Youtube Channel: https://www.youtube.com/@FerdnandFoundation/featured

Today, we are talking about a very popular, yet controversial class of medications - the Benzodiazepines . Let's look at their mechanism of action, clinical indications, pharmacology, risks, withdrawal syndromes, and prescribing guidance. And of course, we'll be tackling the question: what are the risks and benefits of long-term use?

References:

• https://pubmed.ncbi.nlm.nih.gov/30098211/

• https://pubmed.ncbi.nlm.nih.gov/32252539/

• https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates

• https://aapp.org/guideline/benzo

• https://pubmed.ncbi.nlm.nih.gov/40526204/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/

• https://www.ncbi.nlm.nih.gov/books/NBK470159/

• https://www.cambridge.org/core/journals/advances-in-psychiatric-treatment/article/benzodiazepines-for-anxiety-disorders-maximising-the-benefits-and-minimising-the-risks/43A366723CD1B3616BAB08F69FF65A88

Welcome to an introductory episode on anxiety disorders as requested by a long-time listener.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/

https://pmc.ncbi.nlm.nih.gov/articles/PMC5573565/

https://deepblue.lib.umich.edu/bitstream/handle/2027.42/175862/Nesse%20Anxiety%20Disorders%20in%20Evolutionary%20Perspective%202022.pdf?sequence=1

Join us as we talk about Loxapine, an older medication that’s stood the test of time and found a niche in psychiatric practice. This is a revision of an earlier episode, after Dr. Bradley Miller chatted with Dr. Jonathan Meyer at the 2025 APA Conference. Dr. Meyer joins us at the beginning to provide an addendum to the original episode.

Welcome back! Today, we will be talking about Pregabalin, brand-name Lyrica, a similar medication to Gabapentin, and we will specifically be focusing on its use in psychiatry. What are its benefits and drawbacks compared to Gabapentin?

Sources:

- https://pubmed.ncbi.nlm.nih.gov/33563173/

- https://pubmed.ncbi.nlm.nih.gov/39989902/

- https://pmc.ncbi.nlm.nih.gov/articles/PMC3699256/

- https://pubmed.ncbi.nlm.nih.gov/33563173/

Welcome back! Today, we will be talking about Gabapentin, brand-name Neurontin, one of the most commonly-prescribed medications in the United States, and we will specifically be focusing on its use in psychiatry. It is commonly prescribed for anxiety disorders, alcohol use disorder, and sometimes even bipolar disorder! But what does the evidence say?

Sources:

• https://pmc.ncbi.nlm.nih.gov/articles/PMC3619699/#:~:text=The%20FDA%20approved%20gabapentin%20enacarbil,legs%20syndrome%20(RLS)%20symptoms.

• https://journals.lww.com/intclinpsychopharm/Abstract/2017/01000/Pregabalin_for_generalized_anxiety_disorder__an.8.aspx

• https://pmc.ncbi.nlm.nih.gov/articles/PMC9507147/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC4732322/

• https://pubmed.ncbi.nlm.nih.gov/9263379/

• https://pubmed.ncbi.nlm.nih.gov/28988943/

• https://www.cdc.gov/mmwr/volumes/71/wr/mm7119a3.htm

Welcome back! Today, we have renowned guest Dr. Bruce Perry, one of the world's most influential child psychiatrists, to talk to us about his approach to trauma. We will go over Dr. Perry's Neurosequential Model of Therapeutics, which integrates neuroscience with child development. Dr. Perry is also a respected author, co-writing books like The Boy Who Was Raised As a Dog, Born for Love: Why Empathy is Essential and Endangered, as well as What Happened to You? Conversations on Trauma, Resilience and Healing.

Dr. Perry's Website: https://www.bdperry.com/

Dr. Perry's Books: https://www.amazon.com/Books-Bruce-Perry/s?rh=n%3A283155%2Cp_27%3ABruce%2BPerry

Dr. Perry's Youtube Channel: https://www.youtube.com/@infonmn326

Welcome Back! Today we are interviewing Dr. Chris Aiken, Editor-in-Chief of the Carlat Psychiatry Report. We will be speaking about the broad spectrum of mood disorders, how Bipolar Disorder is different from Manic-Depressive Illness, affective temperaments, non-pharmacological treatments, and more! Dr. Aiken's new book, Difficult to Treat Depression, will be released later this year (2025).

Sources:

Akiskal Article: https://pubmed.ncbi.nlm.nih.gov/10550853/

Dr. Aiken's Website: https://chrisaikenmd.com/

Dr. Aiken's Twitter: https://x.com/chrisaikenmd

TEMPS-A Scale: https://chrisaikenmd.com/wp-content/uploads/2024/10/tempsa.pdf

Welcome back! Today, we will review Pramipexole (Mirapex) and take a look at a recent study published in The Lancet Psychiatry regarding its use in treatment-resistant depression.

References:

• https://pubmed.ncbi.nlm.nih.gov/17854248/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC10034846/

• https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00194-4/fulltext